Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Conditions: High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Peritoneal High Grade Serous Adenocarcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Drug: Lenvatinib; Biological: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
November 11, 2021 /
/ in Oncology